Retro-enantio isomer of angiopep-2 assists nanoprobes across the blood-brain barrier for targeted magnetic resonance/fluorescence imaging of glioblastoma

Xie, Ruoxi; Wu, Zhenru; Zeng, Fanxin; Cai, Huawei; Wang, Dan; Gu, Ling; Lui, Su; Guo, Gang; Song, Bin; Li, Jinxing; Wu, Min; Gong, Qiyong

doi:10.1038/s41392-021-00724-y

Cited by 43 publications

(38 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…207,208 Vascular endothelin-2 (Angiopep-2, ANG) peptide from the aprotinin Kunitz domain can specifically target brain cells and bind to low-density lipoprotein receptor-associated protein-1 (LRP1) to achieve targeted delivery, which is overexpressed in the BBB and glioma. [209][210][211] IRGD (CRGD-KGPDC) binds to αvβ3 integrin, which is encapsulated by neuropilin 1 (NRP 1) after its cleavage, and then enters tumour cells through endocytosis. Due to the specificity of these two receptors, iRGD can target multiple tumour cells.…”

Section: Tumour-homing Cppsmentioning

confidence: 99%

The role of cell‐penetrating peptides in potential anti‐cancer therapy

Zhou

Zou

Cheng

et al. 2022

Clinical & Translational Med

View full text Add to dashboard Cite

Due to the complex physiological structure, microenvironment and multiple physiological barriers, traditional anti‐cancer drugs are severely restricted from reaching the tumour site. Cell‐penetrating peptides (CPPs) are typically made up of 5–30 amino acids, and can be utilised as molecular transporters to facilitate the passage of therapeutic drugs across physiological barriers. Up to now, CPPs have widely been used in many anti‐cancer treatment strategies, serving as an excellent potential choice for oncology treatment. However, their drawbacks, such as the lack of cell specificity, short duration of action, poor stability in vivo, compatibility problems (i.e. immunogenicity), poor therapeutic efficacy and formation of unwanted metabolites, have limited their further application in cancer treatment. The cellular uptake mechanisms of CPPs involve mainly endocytosis and direct penetration, but still remain highly controversial in academia. The CPPs‐based drug delivery strategy could be improved by clever design or chemical modifications to develop the next‐generation CPPs with enhanced cell penetration capability, stability and selectivity. In addition, some recent advances in targeted cell penetration that involve CPPs provide some new ideas to optimise CPPs.

show abstract

Section: Tumour-homing Cppsmentioning

confidence: 99%

The role of cell‐penetrating peptides in potential anti‐cancer therapy

Zhou

Zou

Cheng

et al. 2022

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

“…More often than not, diagnosis is delayed, which further impedes the success of the treatment administered [140]. Furthermore, accurate tumor imaging is of immense importance in the pre-operative stage and the location of tumor margins [141]. In this regard, Angiopep-2-modified nanosystems have demonstrated great potential.…”

Section: Diagnostic and Theranostic Applicationsmentioning

confidence: 99%

“…Xie and coworkers [141] constructed a MRI/NIR fluorescence dual-modal imaging nanoprobe by combining superparamagnetic iron oxide NPs (SPIONs) with the fluorescent dye indocyanine. This was further modified with the retro-enantiomer of Angiopep-2 to prevent its degradation by enzymes of the blood and cells.…”

Section: Diagnostic and Theranostic Applicationsmentioning

confidence: 99%

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review

Habib

Singh

2022

Polymers

View full text Add to dashboard Cite

Nanotechnology has opened up a world of possibilities for the treatment of brain disorders. Nanosystems can be designed to encapsulate, carry, and deliver a variety of therapeutic agents, including drugs and nucleic acids. Nanoparticles may also be formulated to contain photosensitizers or, on their own, serve as photothermal conversion agents for phototherapy. Furthermore, nano-delivery agents can enhance the efficacy of contrast agents for improved brain imaging and diagnostics. However, effective nano-delivery to the brain is seriously hampered by the formidable blood–brain barrier (BBB). Advances in understanding natural transport routes across the BBB have led to receptor-mediated transcytosis being exploited as a possible means of nanoparticle uptake. In this regard, the oligopeptide Angiopep-2, which has high BBB transcytosis capacity, has been utilized as a targeting ligand. Various organic and inorganic nanostructures have been functionalized with Angiopep-2 to direct therapeutic and diagnostic agents to the brain. Not only have these shown great promise in the treatment and diagnosis of brain cancer but they have also been investigated for the treatment of brain injury, stroke, epilepsy, Parkinson’s disease, and Alzheimer’s disease. This review focuses on studies conducted from 2010 to 2021 with Angiopep-2-modified nanoparticles aimed at the treatment and diagnosis of brain disorders.

show abstract

“…Nonaka et al reported that IF7, an annexin A1-binding peptide, could overcome BBB and deliver chemotherapeutics to target brain tumors ( Nonaka et al, 2020 ). Xie and coworkers demonstrated that d-peptide ligand of angiopep-2 modified nanoprobes could cross BBB and locate glioma sites ( Xie et al, 2021 ). Lim and collaborators found that dNP2 peptide could penetrate BBB and deliver ctCTLA-4 protein to ameliorate autoimmune encephalomyelitis in mouse models ( Lim et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

BBPpredict: A Web Service for Identifying Blood-Brain Barrier Penetrating Peptides

Chen

Zhang

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Blood-brain barrier (BBB) is a major barrier to drug delivery into the brain in the treatment of central nervous system (CNS) diseases. Blood-brain barrier penetrating peptides (BBPs), a class of peptides that can cross BBB through various mechanisms without damaging BBB, are effective drug candidates for CNS diseases. However, identification of BBPs by experimental methods is time-consuming and laborious. To discover more BBPs as drugs for CNS disease, it is urgent to develop computational methods that can quickly and accurately identify BBPs and non-BBPs. In the present study, we created a training dataset that consists of 326 BBPs derived from previous databases and published manuscripts and 326 non-BBPs collected from UniProt, to construct a BBP predictor based on sequence information. We also constructed an independent testing dataset with 99 BBPs and 99 non-BBPs. Multiple machine learning methods were compared based on the training dataset via a nested cross-validation. The final BBP predictor was constructed based on the training dataset and the results showed that random forest (RF) method outperformed other classification algorithms on the training and independent testing dataset. Compared with previous BBP prediction tools, the RF-based predictor, named BBPpredict, performs considerably better than state-of-the-art BBP predictors. BBPpredict is expected to contribute to the discovery of novel BBPs, or at least can be a useful complement to the existing methods in this area. BBPpredict is freely available at http://i.uestc.edu.cn/BBPpredict/cgi-bin/BBPpredict.pl.

show abstract

Retro-enantio isomer of angiopep-2 assists nanoprobes across the blood-brain barrier for targeted magnetic resonance/fluorescence imaging of glioblastoma

Cited by 43 publications

References 49 publications

The role of cell‐penetrating peptides in potential anti‐cancer therapy

The role of cell‐penetrating peptides in potential anti‐cancer therapy

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review

BBPpredict: A Web Service for Identifying Blood-Brain Barrier Penetrating Peptides

Contact Info

Product

Resources

About